The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.
In recent years, several countries have experienced increases in the incidence of serogroup C meningococcal disease. It can be controlled with older polysaccharide vaccines and particularly the recently developed conjugate vaccines. For 21 developed countries, we investigated the role that economic evaluation played in the decision to introduce the conjugate vaccine into either the routine childhood vaccination schedule, as a mass vaccination 'catch-up' campaign or not at all. A literature review was performed and experts from these countries were contacted. For six countries, we identified published economic evaluations for meningococcal C conjugate vaccination. In four of them (Australia, Canada [Quebec], The Netherlands and the UK) the analyses were performed before a decision about the use of the conjugate vaccine was made. In all of these countries, the economic evaluation offered guidance as to the most efficient way to add the conjugate vaccine to the routine infant immunisation schedule and, in three countries, this advice was adopted by decision makers. In Portugal and Switzerland, initial vaccination decisions were made without the economic evaluations that are influencing current decision making. Of the countries without economic evaluations, six implemented vaccination programmes. Overall, there was a positive correlation between the reported incidence of meningococcal C disease and (a) the decision to vaccinate and (b) performing an economic evaluation. All economic evaluations were modelling studies. The reported cost-effectiveness ratios were sensitive to the age of vaccination, the future meningococcal incidence, vaccine price and some methodological characteristics that varied widely between studies making direct comparisons difficult. In conclusion, in almost all countries where economic evaluations for meningococcal C conjugate vaccinations have been conducted, their results had an important role in the decision-making process. However, in most countries with strongly increasing meningococcal incidence, public health considerations took precedence. In order to improve the international comparability of such studies, firmer national and international modelling guidelines and better adherence to such guidelines seem necessary.
Welte
Robert
R
Institute of Health Economics and Health Care Management, GSF-National Research Center for Environment and Health, Neuherberg, Germany. robert.welte@gsf.de
Trotter
Caroline L
CL
Edmunds
W John
WJ
Postma
Maarten J
MJ
Beutels
Philippe
P
D003362:Cost-Benefit Analysis; D003657:Decision Making; D006801:Humans; D008589:Meningococcal Infections / Q000453:epidemiology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000191:economics*; D014611:Vaccination / Q000191:economics*
D022401:Meningococcal Vaccines; C410218:serogroup C meningococcal conjugate vaccine